{
    "clinical_study": {
        "@rank": "122814", 
        "arm_group": [
            {
                "arm_group_label": "HM11260C (0.3 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks"
            }, 
            {
                "arm_group_label": "HM11260C (1 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks"
            }, 
            {
                "arm_group_label": "HM11260C (2 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Weekly  administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks"
            }, 
            {
                "arm_group_label": "HM11260C (3 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Weekly  administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks"
            }, 
            {
                "arm_group_label": "HM11260C (4 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Weekly  administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Weekly  administration of placebo by subcutaneous injection for 12 weeks"
            }, 
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Active Comparator", 
                "description": "Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the optimal dose or doses of HM11260C, when\n      administered once a week under the skin, to improve the control of blood sugar levels in\n      patients with early-stage type 2 diabetes mellitus (T2DM)."
        }, 
        "brief_title": "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes", 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages eligible for study : 18 years to 74 years\n\n          -  Genders eligible for study : Male and Female\n\n          -  Diagnosed with T2DM\n\n          -  Received diet and exercise therapy with or without metformin monotherapy\n\n          -  HbA1c levels of between \u2265 7.0% and \u2264 10.0%\n\n          -  Females of childbearing potential who are not pregnant and agree to use a reliable\n             method of birth control\n\n          -  Written informed consent must be obtained\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Diagnosis of type 1 diabetes mellitus\n\n          -  Uncontrolled diabetes defined as a FPG level of > 240 mg/dL\n\n          -  A significant change in body weight  in the 3 months before screening\n\n          -  Any history of GI intolerance\n\n          -  Personal or family history of medullary thyroid cancer (MTC) or a genetic condition\n             that predisposes to MTC\n\n          -  Known history of chronic pancreatitis\n\n          -  A history of alcohol or drug abuse or drug addiction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "252", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057172", 
            "org_study_id": "HM-EXC-203"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HM11260C (0.3 mg)", 
                    "HM11260C (1 mg)", 
                    "HM11260C (2 mg)", 
                    "HM11260C (3 mg)", 
                    "HM11260C (4 mg)"
                ], 
                "description": "HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)", 
                "intervention_name": "HM11260C", 
                "intervention_type": "Drug", 
                "other_name": "LAPS-Exendin-4"
            }, 
            {
                "arm_group_label": "Liraglutide", 
                "description": "Liraglutide is a GLP-1 agonist.", 
                "intervention_name": "liraglutide", 
                "intervention_type": "Drug", 
                "other_name": "Victoza"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon-Like Peptide 1", 
                "Exenatide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "glycaemic control", 
            "HM11260C", 
            "placebo", 
            "safety", 
            "tolerability", 
            "type 2 diabetes mellitus", 
            "efficacy", 
            "T2DM", 
            "glycated haemoglobin (HbA1c)", 
            "glycosylated haemoglobin (HbA1c)", 
            "Glucagon-Like Peptide-1 (GLP-1) agonists", 
            "blood sugar levels", 
            "fasting plasma glucose (FPG)"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "contact": {
                "email": "clinical4@hanmi.co.kr", 
                "last_name": "Hanmi Pharmaceutical"
            }, 
            "facility": {
                "address": {
                    "city": "CA", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Hanmi pharmaceutical"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes", 
        "other_outcome": [
            {
                "measure": "Assess the safety and tolerability of HM11260C", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 127"
            }, 
            {
                "measure": "Assess the immunogenicity of HM11260C", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 127"
            }
        ], 
        "overall_contact": {
            "email": "clinical4@hanmi.co.kr", 
            "last_name": "Hanmi Pharmaceutical"
        }, 
        "overall_official": {
            "affiliation": "clinical4@hanmi.co.kr", 
            "last_name": "Hanmi Pharmaceutical", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "Up to 127 days"
        }, 
        "removed_countries": {
            "country": [
                "Czech Republic", 
                "Germany", 
                "Hungary", 
                "Korea, Republic of", 
                "Netherlands", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057172"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Fasting plasma glucose levels (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Up to 127 days"
            }, 
            {
                "measure": "7-point glucose profile", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 127"
            }, 
            {
                "measure": "Other glycaemic control parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 127"
            }, 
            {
                "measure": "Serum lipid profile", 
                "safety_issue": "No", 
                "time_frame": "Up to day 127"
            }, 
            {
                "measure": "Body weight", 
                "safety_issue": "No", 
                "time_frame": "Up to day 127"
            }, 
            {
                "measure": "Number of subjects attaining goal glycosylated haemoglobin (HbA1c) <7%", 
                "safety_issue": "No", 
                "time_frame": "Up to 127 days"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}